Oropharyngeal candidiasis and radiotherapy;Candidose oropharyngée et radiothérapie

Cancer/Radiotherapie

Volumn 16, Issue 3, 2012, Pages 222-229

  Pinel, B ^a   Cassou Mounat, T ^a   Bensadoun, R J ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Mucositis; Oropharyngeal candidiasis; Radiotherapy

Indexed keywords

CANCER PATIENT; CANCER RADIOTHERAPY; CANDIDA; CHEMORADIOTHERAPY; COMORBIDITY; FUNGAL COLONIZATION; FUNGAL STRAIN; HEAD AND NECK CANCER; HUMAN; OROPHARYNX CANDIDIASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY;

CANDIDIASIS; CANDIDIASIS, ORAL; HUMANS; PHARYNGEAL DISEASES; RADIOTHERAPY; XEROSTOMIA;

EID: 84862870443     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.11.004     Document Type: Short Survey

References (52)

1. Soysa N.S., Samaranayake L.P., Ellepola A.N.B. Cytotoxic drugs, radiotherapy and oral candidiasis. Oral Oncol 2004, 40:971-978.
2. Gligorov J., Bastit L., Gervais H., Henni M., Kahila W., Lepille D., et al. Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French Candidoscope Study. Int J Radiat Oncol Biol Phys 2011, 80:532-539.
3. Davies A.N., Brailsford S.R., Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006, 42:698-702.
4. Lalla R.V., Latortue M.C., Hong C.H., Ariyawardana A., D'Amato-Palumbo S., Fischer D.J., et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 2010, 18:985-992.
5. Epstein J.B., Freilich M.M., Le N.D. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993, 76:169-174.
6. Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets 2006, 7:495-504.
7. Havlir D.V., Dubé M.P., McCutchan J.A., Forthal D.N., Kemper C.A., Dunne M.W., et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998, 27:1369-1375.
8. Sweeney M.P., Bagg J., Baxter W.P., Aitchison T.C. Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol 1998, 34:123-126.
9. Finlay I.G. Oral symptoms and candida in the terminally ill. Br Med J (Clin Res Ed) 1986, 292:592-593.
10. Redding S.W., Dahiya M.C., Kirkpatrick W.R., Coco B.J., Patterson T.F., Fothergill A.W., et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 97:47-52.
11. Redding S.W., Kirkpatrick W.R., Coco B.J., Sadkowski L., Fothergill A.W., Rinaldi M.G., et al. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 2002, 40:1879-1881.
12. Dahiya M.C., Redding S.W., Dahiya R.S., Eng T.Y., Kirkpatrick W.R., Coco B.J., et al. Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003, 57:79-83.
13. de Repentigny L., Lewandowski D., Jolicoeur P. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 2004, 17:729-759. [table of contents].
14. Emami E., Séguin J., Rompré P.H., de Koninck L., de Grandmont P., Barbeau J. The relationship of myceliated colonies of Candida albicans with denture stomatitis: an in vivo/in vitro study. Int J Prosthodont 2007, 20:514-520.
15. Tzung K.W., Williams R.M., Scherer S., Federspiel N., Jones T., Hansen N., et al. Genomic evidence for a complete sexual cycle in Candida albicans. Proc Natl Acad Sci U S A 2001, 98:3249-3253.
16. Rhodus N.L., Bloomquist C., Liljemark W., Bereuter J. Prevalence, density, and manifestations of oral Candida albicans in patients with Sjögren's syndrome. J Otolaryngol 1997, 26:300-305.
17. De Bernardis F., Mühlschlegel F.A., Cassone A., Fonzi W.A. The pH of the host niche controls gene expression in and virulence of Candida albicans. Infect Immun 1998, 66:3317-3325.
18. Pirofski L.A., Casadevall A. Rethinking T cell immunity in oropharyngeal candidiasis. J Exp Med 2009, 206:269-273.
19. Samaranayake L.P., MacFarlane T.W. Factors affecting the in vitro adherence of the fungal oral pathogen Candida albicans to epithelial cells of human origin. Arch Oral Biol 1982, 27:869-873.
20. Colina A.R., Aumont F., Deslauriers N., Belhumeur P., de Repentigny L. Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase. Infect Immun 1996, 64:4514-4519.
21. de Repentigny L., Aumont F., Bernard K., Belhumeur P. Characterization of binding of Candida albicans to small intestinal mucin and its role in adherence to mucosal epithelial cells. Infect Immun 2000, 68:3172-3179.
22. Lenander-Lumikari M., Johansson I. Effect of saliva composition on growth of Candida albicans and Torulopsis glabrata. Oral Microbiol Immunol 1995, 10:233-240.
23. Whiteway M., Bachewich C. Morphogenesis in Candida albicans. Annu Rev Microbiol 2007, 61:529-553.
24. Schaller M., Schäfer W., Korting H.C., Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol 1998, 29:605-615.
25. Ripeau J-S., Fiorillo M., Aumont F., Belhumeur P., de Repentigny L. Evidence for differential expression of candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1-transgenic mice. J Infect Dis 2002, 185:1094-1102.
26. Samaranayake L.P., Hughes A., Weetman D.A., MacFarlane T.W. Growth and acid production of Candida species in human saliva supplemented with glucose. J Oral Pathol 1986, 15:251-254.
27. Samaranayake Y.H., MacFarlane T.W., Samaranayake L.P., Aitchison T. The in vitro proteolytic and saccharolytic activity of Candida species cultured in human saliva. Oral Microbiol Immunol 1994, 9:229-235.
28. Nikawa H., Nishimura H., Yamamoto T., Samaranayake L.P. A novel method to study the hyphal phase of Candida albicans and to evaluate its hydrophobicity. Oral Microbiol Immunol 1995, 10:110-114.
29. Luo G., Samaranayake L.P. Candida glabrata, an emerging fungal pathogen, exhibits superior relative cell surface hydrophobicity and adhesion to denture acrylic surfaces compared with Candida albicans. APMIS 2002, 110:601-610.
30. Kaur R., Castaño I., Cormack B.P. Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother 2004, 48:1600-1613.
31. Katiyar S.K., Edlind T.D. Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med Mycol 2001, 39:109-116.
32. Orozco A.S., Higginbotham L.M., Hitchcock C.A., Parkinson T., Falconer D., Ibrahim A.S., et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998, 42:2645-2649.
33. Akpan A., Morgan R. Oral candidiasis. Postgrad Med J 2002, 78:455-459.
34. Samaranayake L.P., Keung Leung W., Jin L. Oral mucosal fungal infections. Periodontol 2000, 49:39-59.
35. Cendras J., Bonnetblanc J.-M. Lichen plan buccal érosif. Ann Dermatol Venereol 2009, 136:458-468. [quiz 457, 469-70].
36. McGrath E.E., Bardsley P., Basran G. Black hairy tongue: what is your call?. CMAJ 2008, 178:1137-1138.
37. Peterson D.E., Bensadoun R.-J., Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol 2010, 21:v261-v265.
38. Rosenthal D.I., Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009, 19:29-34.
39. Jones J.A., Avritscher E.B.C., Cooksley C.D., Michelet M., Bekele B.N., Elting L.S. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006, 14:505-515.
40. Burlage F.R., Coppes R.P., Meertens H., Stokman M.A., Vissink A. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiother Oncol 2001, 61:271-274.
41. Maingon P., Créhange G., Bonnetain F., Ligey-Bartolomeu A., Chamois J., Bruchon Y., et al. Qualité de vie chez les patients traités pour un cancer de la sphère ORL. Cancer Radiother 2010, 14:526-529.
42. Chao K.S., Deasy J.O., Markman J., Haynie J., Perez C.A., Purdy J.A., et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001, 49:907-916.
43. Jabbari S., Kim H.M., Feng M., Lin A., Tsien C., Elshaikh M., et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 2005, 63:725-731.
44. Overgaard J., Mohanti B.K., Begum N., Ali R., Agarwal J.P., Kuddu M., et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 2010, 11:553-560.
45. Bensadoun R.J., Magné N., Marcy P.Y., Demard F. Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol 2001, 258:481-487.
46. Yao M., Karnell L.H., Funk G.F., Lu H., Dornfeld K., Buatti J.M. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous-cell carcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1354-1360.
47. Lee N.Y., de Arruda F.F., Puri D.R., Wolden S.L., Narayana A., Mechalakos J., et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:966-974.
48. Elting L.S., Keefe D.M., Sonis S.T., Garden A.S., Spijkervet F.K.L., Barasch A., et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer 2008, 113:2704-2713.
49. Keefe D.M., Schubert M.M., Elting L.S., Sonis S.T., Epstein J.B., Raber-Durlacher J.E., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007, 109:820-831.
50. Recommandations pour la pratique clinique: Nice, Saint-Paul-de-Vence 2009 « Cancers du sein » et « soins de support ». Oncologie 2009;11:612-793.
51. Bensadoun R-J., Daoud J., El Gueddari B., Bastit L., Gourmet R., Rosikon A., et al. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 2008, 112:204-211.
52. Nicolatou-Galitis O., Velegraki A., Sotiropoulou-Lontou A., Dardoufas K., Kouloulias V., Kyprianou K., et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 2006, 14:44-51.